NORA Manufacturing Sector Strategic Goals
92700A0 - Biomarker Development for Field StudiesStart Date: 10/1/2004
End Date: 9/30/2009
Principal Investigator (PI)Name: Clayton B'hymer
Funded By: Environmental Protection Agency
Primary Goal Addressed6.0
Secondary Goal AddressedNone
Attributed to Manufacturing75%
Biomarker Development for Field Studies is an ongoing methods development project for the Molecular and Genetic Monitoring Team designed to provide the biomonitoring analyses required for field investigations of occupational exposures. Biomarker methods will be developed and applied for occupational toxicants to assess exposure and susceptibility and will target the Manufacturing, and Healthcare and Social Assistance Sectors. In FY09, efforts will continue to the study biomarkers of susceptibility, as they related to metabolism and DNA repair pathways, with respect to acrylamide and include further proteomic study. These biomarkers methods will improve the assessment of internal dose and early biological effect in field studies of occupational exposures. Some other smaller projects will be involved and collaborative work with the EPA.
The purpose of this Molecular and Genetics Monitoring Team "umbrella" project is to identify and develop biomarkers of exposure, biomarkers of susceptibility and biomarkers of effect for occupational toxicants which is an integral part of the biomonitoring program at NIOSH. This project will provide guidance for branch collaborative studies involving biomarker research that are not large enough in scope to be stand alone. Biomarkers have an important application for human field studies. Workers can be better protected by the knowledge gained from more accurate determinations of exposure from the use of the appropriate biomarkers. This project addresses the need to relate exposure and susceptibility markers to markers of early effects and to determine which markers must be characterized to best reflect exposure or early indicators of disease.
• Applications of biomarker methods for occupational toxicants to assess exposure with internal or external partners will be tracked and reported.
All forms of biomarkers are routinely incorporated into the design of both epidemiological and health outcome studies so that exposure and effects of exposure can be more accurately characterized. Biomarker studies are needed that relate internal dose with external exposure and relate exposure to disease so that the associated health risk can be fully understood. Biomarker data can be used to document the existence of an exposure problem, a health effect related to exposure, or to indicate the adequacy of control technologies and intervention strategies. Biomarkers studied and developed during this project will have application for exposure assessment studies (both planned as well as requests from partners for assistance), and for evaluating intervention effectiveness. For FY09, activities will complete data analysis for healthcare worker study and proteomic method development of biomarkers in collaboration of the acrylamide worker project as well as characterization of polymorphisms in DNA repair pathways in samples collected from ongoing field studies of acrylamide workers. It has been estimated that occupational exposures could be attributed to as many as 40,000 new cases of cancer a year within the United States. Specifically for acrylamide, an NOES survey has indicated that as many as 10,000 workers are exposed to acrylamide in the United States. This project addresses goals in both the Healthcare and Social Assistance (09PPHSASG2) and Manufacturing (09PPMNFSG6) Sectors, specifically to the Activity/Output Goal 2a.1.2 (09PPHSAAOG2a1.2): Evaluate exposures to carcinogens and teratogens in the HSA Sector. This project also aligns to the Cancer, Reproductive and Cardiovascular Diseases Cross Sector Activity/Output Goal 1.1.3. (09PPCRCAOG1.1.3); Develop and evaluate biomonitoring methods for the determination of carcinogen exposures and health effects in workers and Activity/Output Goal 1.1.6. (09PPCRCAOG1.1.6); Assess how cancer risk is influenced by the interaction of human genetic variation with modifiable risk factors and the Exposure Assessment Cross Sector Intermediate Goal 2.4 (09PPEXAIG2.4): Develop biomonitoring methods including biomarkers that are useful for mixed exposures.